(BIIB) announced an update on their ongoing clinical study.Claim 50% Off TipRanks Premium and Invest with Confidence Unlock hedge-fund level data and powerful investing tools designed to help you ...

Rating for BiogenBIIB jumped into a new percentile Monday, with an increase from 80 to 84.Please watch the video at Investors ...

With notable therapies from Biogen, Sarepta and MacroGenics failing to show efficacy in pivotal or confirmatory trials, experts question the use of biomarker evidence for approval while one former ...

Get insights on Biogen’s Leqembi sales outlook, clinical value, risks, and what new drug approvals may mean for investors.

Bitcoin-focused firm Strategy has successfully maintained its position in the Nasdaq 100, extending its stay in the influential index as debates intensify over the sustainability of crypto treasury ...

In this video, Brian T. Hill, MD, PhD, discusses data from the Smart Stop trial assessing the effects of a novel targeted combination therapy in patients with newly diagnosed diffuse large B-cell ...

Biogen has taken up an option on a technology developed by Denali that it thinks could help improve the safety and efficacy of amyloid-targeting drugs for Alzheimer’s disease. The technology – called ...

Strategy stock maintains Nasdaq 100 inclusion after rebalancing while MSCI reviews digital asset treasury companies. Decision ...

Bitcoin hoarding giant Strategy clung to its place in the Nasdaq 100 on Friday, continuing its year-long ‍stint in the ...

First Patient Expected to be Dosed Next Week with Intranasal Foralumab PET Scan Shows Presence of Untreated Neuroinflammation ...

Alzheimer's trials testing Novo Nordisk’s blockbuster GLP-1 drug semaglutide, despite their failure, underscore a shift to ...

With the other premium services, you can dive deep into additional metrics, portfolios, commentary and information about Biotechnology stocks as well as other industrys. Choosing Which of the 4 Best ...